EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial

Eric Morand iD, Marilyn Pike, Joan T Merrill iD, Ronald van Vollenhoven, Victoria P Werth iD, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee und 1 weitere

Arthritis & Rheumatology · 2023-02 · 75 (2) · 242-252

DOI: 10.1002/art.42391 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 11.11.2022. Verfasst von Eric Morand und 12 weiteren Autor:innen. Beteiligte Einrichtung: Monash University and Department of Rheumatology, Monash Health, Victoria, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 251-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol-Myers Squibb Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE).

Methods

Adults with active SLE were enrolled from 162 sites in 17 countries. Patients (n = 363) were randomized 1:1:1:1 to receive deucravacitinib 3 mg twice daily, 6 mg twice daily, 12 mg once daily, or placebo. The primary end point was SLE Responder Index 4 (SRI‐4) response at week 32. Secondary outcomes assessed at week 48 included SRI‐4, British Isles Lupus Assessment Group–based Composite Lupus Assessment (BICLA) response, Cutaneous Lupus Erythematosus Disease Area and Severity Index 50 (CLASI‐50), Lupus Low Disease Activity State (LLDAS), and improvements in active (swollen plus tender), swollen, and tender joint counts.

Results

At week 32, the percentage of patients achieving SRI‐4 response was 34% with placebo compared to 58% with deucravacitinib 3 mg twice daily (odds ratio [OR] 2.8 [95% confidence interval (95% CI) 1.5, 5.1]; P < 0.001 versus placebo), 50% with 6 mg twice daily (OR 1.9 [95% CI 1.0, 3.4]; P = 0.02 versus placebo), and 45% with 12 mg once daily (OR 1.6 [95% CI 0.8, 2.9]; nominal P = 0.08 versus placebo). Response rates were higher with deucravacitinib treatment for BICLA, CLASI‐50, LLDAS, and joint counts compared to placebo. Rates of adverse events were similar across groups, except higher rates of infections and cutaneous events, including rash and acne, with deucravacitinib treatment. Rates of serious adverse events were comparable, with no deaths, opportunistic infections, tuberculosis infections, major adverse cardiovascular events, or thrombotic events reported.

Conclusion

Deucravacitinib treatment elicited higher response rates for SRI‐4 and other end points compared with placebo, with an acceptable safety profile, in adult patients with active SLE. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLupus Erythematosus, SystemicAdultHumansTYK2 KinaseTreatment OutcomeDouble-Blind MethodSeverity of Illness IndexHeterocyclic Compounds

Substanzen

Antibodies, Monoclonal, HumanizedTYK2 KinasedeucravacitinibHeterocyclic Compounds

Autor:innen und Institutionen

  • Monash University and Department of Rheumatology, Monash Health, Victoria, Australia.
  • MedPharm Consulting, Inc., Raleigh, North Carolina.
  • Oklahoma Medical Research Foundation, Oklahoma City.
  • Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia.
  • Bristol Myers Squibb, Princeton, New Jersey.

ORCID-Profile: Eric Morand, Joan T Merrill, Victoria P Werth

Förderung

  • Bristol-Myers Squibb Canada

Zitieren

APA

Morand, E., Pike, M., Merrill, J. T., van Vollenhoven, R., Werth, V. P., Hobar, C., Delev, N., Shah, V., Sharkey, B., Wegman, T., Catlett, I., Banerjee, S., & Singhal, S. (2023). Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial. Arthritis & Rheumatology, 75(2), 242-252. https://doi.org/10.1002/art.42391

Vancouver

Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial. Arthritis & Rheumatology. 2023;75(2):242-252. doi:10.1002/art.42391

BibTeX
@article{Morand2023,
  author = {Morand, Eric and Pike, Marilyn and Merrill, Joan T and van Vollenhoven, Ronald and Werth, Victoria P and Hobar, Coburn and Delev, Nikolay and Shah, Vaishali and Sharkey, Brian and Wegman, Thomas and Catlett, Ian and Banerjee, Subhashis and Singhal, Shalabh},
  title = {Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  volume = {75},
  number = {2},
  pages = {242--252},
  doi = {10.1002/art.42391}
}
Kostenlos starten →